Analysis of Severe Adverse Events Reported Among Patients Receiving Isoniazid-Rifapentine Treatment for Latent Mycobacterium tuberculosis Infection—United States, 2012–2016 | Zendy

Kristine M Schmit | Zendy; Jonathan M. Wortham | Zendy; Christine Ho | Zendy; Krista M. Powell | Zendy

Open Access

Analysis of Severe Adverse Events Reported Among Patients Receiving Isoniazid-Rifapentine Treatment for Latent Mycobacterium tuberculosis Infection—United States, 2012–2016

Author(s) -

Kristine M Schmit,

Jonathan M. Wortham,

Christine Ho,

Krista M. Powell

Publication year - 2020

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciaa286

Subject(s) - rifapentine , medicine , isoniazid , latent tuberculosis , mycobacterium tuberculosis , tuberculosis , adverse effect , extensively drug resistant tuberculosis , virology , pathology

We analyzed data from 2012 to 2016 for patients who were hospitalized or who died after ≥1 dose of isoniazid-rifapentine for treatment of latent Mycobacterium tuberculosis infection. No patients died; 15 were hospitalized. Nine patients experienced hypotension, and 5 had elevated serum aminotransferases, reinforcing the need for vigilant monitoring during treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research